ADIA (Adia Med) EBIT: $-0.41 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADIA Adia Med Inc ADIA
14 GF Score
Price $0.15
! 4 Warning Signs
View Full Analysis

What is Adia Med EBIT?

Adia Med ADIA 14 EBIT is $-0.41 Mil as of Mar. 2026. GuruFocus rates ADIA with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

Adia Med's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-0.15 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.41 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Adia Med's annualized ROC % for the quarter that ended in Mar. 2026 was -61.14%. Adia Med's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -240.32%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Adia Med's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2.73%.

Adia Med  (OTCPK:ADIA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Adia Med's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-0.608 * ( 1 - 0% )/( (0.538 + 1.451)/ 2 )
=-0.608/0.9945
=-61.14 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.595 - 0.04 - ( 0.079 - max(0, 0.145 - 0.162+0.079))
=0.538

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.777 - 0.077 - ( 0.143 - max(0, 1.11 - 0.359+0.143))
=1.451

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Adia Med's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.608/( ( (0.247 + max(0.028, 0)) + (0.231 + max(-0.08, 0)) )/ 2 )
=-0.608/( ( 0.275 + 0.231 )/ 2 )
=-0.608/0.253
=-240.32 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.033 + 0.025 + 0.024) - (0.04 + 0.014 + -2.7755575615629E-17)
=0.028

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.079 + 0.11 + 0.026) - (0.077 + 0.218 + 2.2204460492503E-16)
=-0.08

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Adia Med's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-0.405/14.827
=-2.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adia Med EBIT Related Terms

Adia Med EBIT Historical Data

* Premium members only.

The historical data trend for Adia Med's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adia Med EBIT Chart

Adia Med Annual Data
Trend Dec24 Dec25
EBIT
-0.18 -0.36

Adia Med Quarterly Data
Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial -0.11 -0.13 0.09 -0.21 -0.15

ADIA vs GBCS, CCM, CDIX: EBIT Comparison

For the Medical Care Facilities subindustry, Adia Med's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adia Med EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Adia Med's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Adia Med's EV-to-EBIT falls into.


ADIA
14GF Score
Adia Med Inc ADIA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adia Med EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-0.41 Mil mean?
Adia Med (ADIA) has a EBIT of $-0.41 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Adia Med.
Is Adia Med's EBIT too high?
Adia Med's current EBIT is $-0.41 Mil. Overall, Adia Med has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Adia Med's EBIT compare to GBCS and CCM?
Adia Med's EBIT of $-0.41 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Adia Med. Adia Med's current EBIT is $-0.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adia Med stock overvalued right now?
Adia Med (ADIA) has a current EBIT of $-0.41 Mil. The current EBIT is $-0.41 Mil. Adia Med's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Adia Med (ADIA), the current EBIT is $-0.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adia Med Business Description

Address 1561 West Fairbanks Avenue, Suite 205, Winter Park, FL, USA, 32789
Adia Nutrition Inc focus is to work closely with healthcare providers and health insurance companies to facilitate and provide Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Its products and the deployment of the therapies utilizing its products address various orthopedic issues, pain management, and wound repair. In addition, its products are able to be utilized in various other therapies to address anti-aging issues and other tissue repair desires. It operates in three segments The Biolete segment comprises the sale of supplements; Adia Med performs stem cell treatments to patients; and Adia Labs procures and sells stem cell products to outside clinics or to Adia Med. It derives revenue from Sales of supplements, Medical procedures, Sales of biologics and ancillary products.
14GF Score

Get the complete analysis for ADIA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price